Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2022-01-01
Serie:Cancer Treatment and Research Communications
Soggetti:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Accesso online:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi